Compare Medpace Holdings Inc (MEDP) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Marathon Petroleum Corp — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Marathon Petroleum Corp trades at $455.03 (market cap $130.12B). The key difference: Marathon Petroleum Corp is far larger — about 7.7× Medpace Holdings Inc's market cap, and Marathon Petroleum Corp pays a 0.86% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Marathon Petroleum Corp for 54 Days on average.
| MEDP | MPC | |
|---|---|---|
Market Cap | $16.82B | $130.12B |
Volume | 223,093 | 2,749,647 |
Sector | Health | Energy |
52-Week High | $630.19 | $463.34 |
52-Week Low | $393.42 | $162.63 |
Typical Hold Time | 14 Days | 54 Days |
Enterprise Value | $16.44B | $156.64B |
Dividend Yield | — | 0.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Marathon Petroleum (MPC) trades at $463.34, up 4.77% today, reflecting strong momentum amid favorable refining margins. The stock exhibits bullish technical signals with consistent earnings beats and robust profitability metrics, including a 47.9% ROE. Recent news highlights its outperformance versus integrated oil peers, driven by tight global refining capacity and resilient demand.
Outlook remains positive with analyst consensus favoring Buy ratings (75.76%) and a $426.30 price target, though current price exceeds this. Key risks include potential diesel export bans and volatile crack spreads. Revenue is projected to rebound to $153.6B in 2026, supporting further upside if margin strength persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
